Spots Global Cancer Trial Database for squamous cell carcinoma of the bladder
Every month we try and update this database with for squamous cell carcinoma of the bladder cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | NCT00024349 | Bladder Cancer | fluorouracil mitomycin C radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder | NCT01124682 | Bladder Cancer | diagnostic cyst... diffusion-weigh... implanted fiduc... quality-of-life... 3-dimensional c... image-guided ra... selective exter... | 18 Years - | National Cancer Institute (NCI) | |
| Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer | NCT00024349 | Bladder Cancer | fluorouracil mitomycin C radiation thera... | 18 Years - | National Cancer Institute (NCI) | |
| Sacituzumab Govitecan With or Without Atezolizumab Immunotherapy in Rare Genitourinary Tumors (SMART) Such as Small Cell, Adenocarcinoma, and Squamous Cell Bladder/Urinary Tract Cancer, Renal Medullary Carcinoma and Penile Cancer | NCT06161532 | Small Cell Carc... Small Cell Carc... Squamous Cell C... Squamous Cell C... Primary Adenoca... Primary Adenoca... Renal Medullary... Squamous Cell C... | Sacituzumab gov... Atezolizumab | 18 Years - 120 Years | National Institutes of Health Clinical Center (CC) | |
| Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer | NCT01611662 | Distal Urethral... Proximal Urethr... Squamous Cell C... Stage II Bladde... Stage III Bladd... Urethral Cancer... | gemcitabine hyd... cisplatin therapeutic con... laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | NCT00112905 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer | NCT01196403 | Bladder Cancer | questionnaire a... quality-of-life... robot-assisted ... therapeutic con... therapeutic lap... | 18 Years - | National Cancer Institute (NCI) | |
| Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | NCT00112905 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Regional Transi... Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... Urethral Cancer... | sorafenib tosyl... laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer | NCT01611662 | Distal Urethral... Proximal Urethr... Squamous Cell C... Stage II Bladde... Stage III Bladd... Urethral Cancer... | gemcitabine hyd... cisplatin therapeutic con... laboratory biom... | 18 Years - | Fox Chase Cancer Center | |
| Adjuvant Radiation for High Risk Bladder Cancer | NCT01954173 | Bladder Cancer Squamous Cell C... Stage III Bladd... Stage IV Bladde... Transitional Ce... | 3D conformal ra... | 18 Years - | Emory University | |
| Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer | NCT00005831 | Metastatic Tran... Recurrent Bladd... Recurrent Trans... Squamous Cell C... Stage IV Bladde... Transitional Ce... | trastuzumab paclitaxel carboplatin gemcitabine hyd... laboratory biom... | - | National Cancer Institute (NCI) | |
| Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer | NCT00002684 | Bladder Cancer Urethral Cancer | cisplatin ifosfamide paclitaxel | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment | NCT00016237 | Bladder Cancer Kidney Cancer Lung Cancer | tucotuzumab cel... | 18 Years - | EMD Serono | |
| Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract | NCT00006026 | Bladder Cancer Transitional Ce... Urethral Cancer | rubitecan | 18 Years - | European Organisation for Research and Treatment of Cancer - EORTC | |
| VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium | NCT00407485 | Adenocarcinoma ... Distal Urethral... Metastatic Tran... Proximal Urethr... Recurrent Bladd... Recurrent Trans... Recurrent Ureth... Squamous Cell C... Stage III Bladd... Stage III Ureth... Stage IV Bladde... Transitional Ce... Urethral Cancer... | ziv-aflibercept pharmacological... | 18 Years - | National Cancer Institute (NCI) | |
| Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer | NCT01094964 | Bladder Cancer | BCG solution recombinant int... epirubicin hydr... mitomycin C laboratory biom... hyperthermia tr... quality-of-life... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
